Clinical Trial

A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat

Name: A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat — clinical trial record (NCT07608770)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

A phase 2b, randomized, placebo-controlled study with long-term re-treatment to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat

Protocol Amendment History 1 change

critical Recruitment opened 2026-06-05

Trial Details

NCT Number	NCT07608770
Lead Sponsor	Caliway Biopharmaceuticals Co., Ltd.
Conditions	Subcutaneous Fat
Enrollment	250 participants
Start Date	2026-06
Primary Completion	2027-04 (estimated)
Study Completion	2027-11 (estimated)
Updated on ClinicalTrials.gov	2026-06-04